Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF MT200605 FOR ACUTE ISCHEMIC STROKE (AIS) REACHED PRIMARY ENDPOINT

The board of directors (the "**Board**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial (the "**Clinical Trial**") of the Group's independently developed drug candidate MT200605 for the treatment of AIS, has obtained top-line results. Results indicated that the Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes.

The Clinical Trial is a multi-center, randomized, double-blind and placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of MT200605, with a total of 360 subjects enrolled.

Result analysis showed that:

- In terms of efficacy, the primary efficacy endpoint results (the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 at 90 days) demonstrated that the proportions of patients achieving mRS 0–1 in both the medium-dose and high-dose groups of MT200605 were higher than that in the placebo group, with the high-dose group demonstrating a more than 100% relative increase in the proportion of patients achieving favorable functional outcomes compared with the placebo group. Logistic regression analysis showed that the difference between the high-dose group and the placebo group was statistically significant. The secondary efficacy endpoints also demonstrated a consistent favourable efficacy trend.

- In terms of safety, MT200605 demonstrated a favorable safety and tolerability profile, with no serious adverse events (SAEs) related to the investigational drug occurred throughout the study period. Treatment-emergent adverse events (TEAEs) of Grade ≥3 were comparable among the treatment groups, and no new significant safety concerns were identified.

- Overall, MT200605 demonstrated significant and robust efficacy in patients with AIS, with a favorable safety and tolerability profile.

About MT200605: To the knowledge of the Company, MT200605 is the only neuroprotective agent globally that can penetrate the blood-brain barrier ("**BBB**") and act on the BDNF/TrkB pathway, while also exerting antioxidative stress effects and alleviating microcirculatory obstruction caused by calcium ion-induced vascular smooth muscle contraction, thereby achieving comprehensive blockade of ischemic cascade injury induced following AIS while promoting neural regeneration and remodeling.

Participating in the National Major Science and Technology Project: In collaboration with Beijing Tiantan Hospital, Capital Medical University, the Group participated in the project entitled "Development and Clinical Trial Validation of Innovative Drugs for the Prevention and Treatment of Cardiovascular and Cerebrovascular Thromboembolic Diseases" under the National Major Science and Technology Project for Innovative Drug Development. The Group primarily undertook research work relating to the clinical development and trial validation of MT200605 (a TrkB small molecule agonist) for patients with AIS, with the aim of evaluating its efficacy and safety.

Grant of Orphan Drug Designation: In addition to its development for AIS, MT200605 is also being developed for the treatment of Huntington's Disease ("**HD**"). MT200605 is designed to selectively activate the TrkB signaling pathway and exert dual neuroprotective and antioxidant effects to preserve the structure and function of neuronal tissues. Preclinical studies have demonstrated its potential to directly reduce the aggregation of mutant huntingtin protein ("**mHTT**"), thereby providing a potential disease-modifying therapeutic approach for HD. In March 2026, MT200605 has been granted the orphan drug designation by the Food and Drug Administration of the United States (FDA) for the treatment of HD.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 3 August 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.